1 **A single full-length VAR2CSA ectodomain variant purifies broadly**
2 **neutralizing antibodies against placental malaria isolates**
3 Justin Y. A. Doritchamou, Jonathan P. Renn, Bethany Jenkins, Michal Fried, Patrick E. Duffy*
4 Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious
5 Diseases, National Institutes of Health, Bethesda, MD, USA.
6 ***Corresponding Author:** patrick.duffy@nih.gov

7

Abstract

Placental malaria (PM) is a deadly syndrome most frequent and severe in first pregnancies. PM results from accumulation of *Plasmodium falciparum*-infected erythrocytes (IE) that express the surface antigen VAR2CSA and bind to chondroitin sulfate A (CSA) in the placenta. Women become PM-resistant over successive pregnancies as they develop anti-adhesion and anti-VAR2CSA antibodies, supporting VAR2CSA as the leading PM-vaccine candidate. However, the first VAR2CSA subunit vaccines failed to induce broadly neutralizing antibody and it is known that naturally acquired antibodies target both variant-specific and conserved epitopes. It is crucial to determine whether effective vaccines will require incorporation of many or only a single VAR2CSA variants. Here, IgG from multigravidae was sequentially purified on five full-length VAR2CSA ectodomain variants, thereby depleting IgG reactivity to each. The five VAR2CSA variants purified ~0.7% of total IgG and yielded both strain-transcending and strain-specific reactivity to VAR2CSA and IE-surface antigen. In two independent antibody purification/depletion experiments with permuted order of VAR2CSA variants, IgG purified on the first VAR2CSA antigen displayed broad cross-reactivity to both recombinant and native VAR2CSA variants, and inhibited binding of all isolates to CSA. IgG remaining after depletion on all variants showed significantly reduced binding-inhibition activity compared to initial total IgG. These findings demonstrate that a single VAR2CSA ectodomain variant displays conserved epitopes that are targeted by neutralizing (or binding-inhibitory) antibodies shared by multiple parasite strains, including maternal isolates. This suggests that a broadly effective PM-vaccine can be achieved with a limited number of VAR2CSA variants.

Key words: Pregnancy, malaria, vaccine, VAR2CSA, variant, blocking antibody

Introduction

Plasmodium falciparum infection in pregnant women causes placental malaria (PM) when *P. falciparum*-infected erythrocytes (IE) accumulate in the intervillous spaces of the placenta. PM has been linked to several adverse pregnancy outcomes (Steketee et al., 2001; Guyatt and Snow, 2001; Desai et al., 2007; Moore et al., 2017), and first-time mothers are most vulnerable (Brabin, 1983). Over successive pregnancies, PM and the related sequelae become less prevalent (Guyatt and Snow, 2001). Susceptibility to PM has been attributed to *P. falciparum* parasites that bind chondroitin sulphate-A (CSA) expressed by the placental syncytiotrophoblast (Fried and Duffy, 1996), and express the variant surface antigen VAR2CSA (Salanti et al., 2003; Tuikue Ndam et al., 2005). Conversely, the decrease in PM-related poor pregnancy outcomes with increasing parity is associated with the acquisition of functional antibodies to CSA-binding IE (Fried and Duffy, 1998; Ricke et al., 2000) and antibodies to VAR2CSA (Salanti et al., 2004; Ndam et al., 2015). Such functional antibodies have been characterized for two major functions: 1) blocking CSA-binding of VAR2CSA-expressing parasites; and 2) opsonizing IE to promote phagocytosis (Fried and Duffy, 1998; Ricke et al., 2000; Duffy and Fried, 2003; Keen et al., 2007; Ataíde et al., 2011).

Hence, VAR2CSA represents the leading candidate for PM vaccine development. VAR2CSA is a large (~318-478 kDa) multidomain transmembrane protein, a member of the *P. falciparum* erythrocyte membrane protein 1 (PfEMP1) family encoded by *var* genes (Gardner et al., 2002; Hviid and Jensen, 2015). The cysteine-rich ectodomain is formed by N-terminal sequence (NTS), six and sometimes more Duffy-binding-like (DBL) domains as well as interdomain (ID) regions (Kraemer and Smith, 2006; Doritchamou et al., 2019). Recent studies showed that VAR2CSA ectodomain structure includes a stable core (NTS-DBL1X-ID1-DBL2X-ID2-DBL3X-DBL4e-ID3) flanked by a flexible arm (DBL5e-DBL6e), and the receptor interaction involves CSA threading through two channels that formed within the stable core (Ma et al., 2021; Wang et al., 2021). Multiple individual DBL domains of VAR2CSA interact with CSA *in vitro* (Dahlbäck et al., 2011; Clausen et al., 2012; Ma et al., 2021) and induce functional antibodies in animals (Bigey et al., 2011; Fried et al., 2013; Nielsen and Salanti, 2015; Chêne et al., 2018). Two subunit vaccine candidates (called PAMVAC and PRIMVAC) from the N-terminal region of VAR2CSA were recently tested in phase 1 trials (Mordmüller et al., 2019; Sirima et al., 2020). Both trial teams reported that VAR2CSA subunit vaccines were safe, immunogenic and induced functional anti-adhesion antibodies in malaria-naïve and malaria-exposed women (Mordmüller et al., 2019; Sirima et al., 2020). However, functional activity was primarily against homologous parasites (same VAR2CSA sequence as vaccine) and low or absent against heterologous parasites (Sirima et al., 2020), suggesting the vaccine antigen failed to display functional epitopes shared across multiple *P. falciparum* variants (reviewed in (Doritchamou et al., 2021)).

Similarly, VAR2CSA fragments (single or double domains) fail to purify the broadly neutralizing activity of sera from PM-resistant multigravidae (Doritchamou et al., 2016). Although VAR2CSA fragments (including constructs similar to PAMVAC vaccine) purified antibodies with CSA-binding inhibitory activity against homologous parasites, broadly neutralizing activity was neither purified nor depleted after passing sera over several VAR2CSA domains and variants (Doritchamou et al., 2016). These data supports the hypothesis that functional antibodies to VAR2CSA may target

conformational epitopes not displayed by any individual domain: for example, the strain-transcending human monoclonal antibody PAM1.4 is specific for an unknown conformational epitope on full-length VAR2CSA (Barfod et al., 2007).

Naturally acquired antibodies of multiparous women exhibit broadly neutralizing anti-adhesion activity (Fried and Duffy, 1998; Ricke et al., 2000; Ndam et al., 2015). However, it is unknown whether broadly binding-inhibitory antibodies target conserved epitopes on VAR2CSA or rather result from the cumulative repertoire of antibodies against variant specific epitopes. In this study, we investigate the hypothesis that full-length VAR2CSA ectodomain may capture naturally acquired antibodies from multigravidae plasma with greater breadth of neutralizing activity than previously achieved by multiple VAR2CSA domains. We show that a single ectodomain can purify strain-transcending IgG as well as the bulk of functional activity naturally acquired by multigravid women. In parallel, the depletion of IgG reactivities to five variants of full-length VAR2CSA resulted in significantly diminished strain-transcending anti-adhesion activity. These data suggest that full-length VAR2CSA ectodomain displays functional epitopes that are absent in subunit VAR2CSA fragments and provide a basis to design improved vaccines.

Results

Depletion of IgG on five VAR2CSA ectodomains significantly reduces broad neutralizing activity

IgG specific to full-length VAR2CSA ectodomains was purified from a plasma pool prepared using samples from multigravid women participating in the previously described Immuno-epidemiology (IMEP) study (Fried et al., 2018) (see **Methods** and **Figure 1** for experimental design).

Figure 1: Flow chart of the experimental design

The affinity purification of IgG specific to five VAR2CSA ectodomain variants yielded a combined ~386.1 µg of VAR2CSA-specific IgG, representing about 0.7% of the original total IgG (**Table 1**). The highest yields of purified IgG were obtained on the first two variants (NF54 and 7G8) totaling 76% of the IgG purified on all five variants.

Table 1: Purification yields of purified IgG

Order of depletion	IgG	Yield
-	Total IgG	58000µg
1	Fv2-NF54 IgG	145.6µg
2	Fv2-7G8 IgG	148.9µg
3	Fv2-FCR3 IgG	53.4µg
4	Fv2-HB3 IgG	14.5µg
5	Fv2-M. Camp IgG	23.7µg

Variable levels of IgG reactivity to seven recombinant VAR2CSA ectodomains was measured in the pre-depletion total IgG. As expected, IgG reactivity to NF54, 7G8, FCR3, HB3 and M. Camp variants were successfully depleted from the total IgG pool, as demonstrated by the absence of reactivity in each post-depletion sample (**Figure 2A, figure supplement 1A**). Of note, substantially reduced reactivity to M920 and M200101 (not used in the affinity purification assay) was seen in the post-depletion total IgG, indicating that cross-reactive IgG to these two antigens was also depleted.

Figure 2: Depletion of VAR2CSA-specific IgG and activity of Total IgG purified from Malian multigravidae

Similarly, reactivity to native VAR2CSA measured on the IE surface by flow cytometry was depleted in the post-depletion IgG when tested on NF54, WF12/7G8, FCR3 and Malayan Camp (M. Camp) isolates (**Figure 2B, figure supplement 1B**). Of note, WF12 (here named WF12/7G8) is a progeny of 7G8 X GB4 (Hayton et al., 2008) and its genome encodes the 7G8 VAR2CSA variant (**Figure 2-figure supplement 2**) Further, reactivity of post-depletion total IgG to native VAR2CSA of heterologous maternal isolates (M2022170, M2001190 and M0736) was substantially reduced versus the pre-depletion total IgG.

Importantly, depletion of IgG on the five VAR2CSA variants also reduced CSA-binding inhibition activity in the total IgG, being abolished against some isolates and significantly reduced against others (**Figure 2C**). The inhibition activity of the original pre-depletion total IgG sample was >65% against all parasite lines including recently adapted maternal isolates, except for FCR3 whose binding was inhibited 33% (**Figure 2C**). After the depletion of VAR2CSA-specific IgG, the inhibition activity was substantially reduced, with the % reduction (measured as $((\text{pre-depletion \% inhibition} - \text{post-depletion \% inhibition}) / (\text{pre-depletion \% inhibition}) \times 100)$) ranging from 45% against M2022170 to 87% against NF54 (**Figure 2-figure supplement 3**). CSA-binding inhibition activity was substantially reduced against the three maternal isolates (including M2022170), implying that a significant fraction of cross-inhibitory IgG to the maternal isolates were also depleted on the heterologous VAR2CSA antigens.

Highly cross-reactive IgG is purified on the first full-length VAR2CSA antigen

VAR2CSA-purified IgG exhibited cross-reactivity in ELISA to different variants including M920 and M200101 (**Figure 3A**), although the degree of this dropped substantially after the first purification. As expected, reactivity was largely absent when IgG was tested against VAR2CSA variants previously used in the series of purifications/depletions. Thus, NF54-purified IgG (NF54-IgG) reacted to homologous and heterologous VAR2CSA antigens at the highest level of any IgG, while IgG purified on M. Camp (the last antigen used in the purification/depletion series) showed no

139 cross-reactivity to NF54, 7G8, FCR3 or HB3 variants. Notably, each variant purified specific
140 reactivity to itself, albeit at lower OD values than that seen with the initial NF54 purification, which
141 may indicate the greater abundance and/or greater affinity of cross-reactive versus variant-specific
142 IgG acquired by multigravidae.

143

144
145
146

Figure 3: Reactivity of the purified VAR2CSA-specific IgG to different full-length VAR2CSA antigens and *P. falciparum* isolates

147
148

Similar to ELISA, flow-cytometry revealed strain-transcending reactivity to native antigen, though this decreased after the first (NF54) and again after the second (7G8) affinity columns. NF54-IgG showed the greatest breadth of reactivity (defined as the number of isolates recognized) with detectable reactivity to IE surface of all parasites including the maternal isolates (known to be polyclonal parasite samples). NF54-IgG also displayed the highest level of reactivity to all the isolates (**Figure 3B**). Compared to NF54-IgG, IgG subsequently purified on 7G8, FCR3 and M. Camp ectodomains demonstrated lower surface reactivity to the homologous parasite and lower cross-reactivity to the maternal isolates. Although the HB3-IgG was not tested against its homologous parasite line, this antigen-specific purified IgG displayed weaker cross-reactivity to different heterologous lab strain parasites compared to the other purified IgG. As with ELISA, reactivity by flow cytometry was lost against parasite isolates after their corresponding recombinant ectodomain had been used in the series of depletion/purifications, attesting to the complete depletion of homologous IE-surface reactivity by each homologous antigen.

A single full-length VAR2CSA variant purifies the bulk of naturally acquired binding-inhibitory IgG

Strong cross-inhibitory activity of IgG purified on VAR2CSA was observed in assays that measure inhibition of parasite binding to CSA (**Figure 4, figure supplement 1**). IgG binding-inhibition activity was normalized (nBIA) as a percentage of the pre-depletion total IgG, with the assumption that maximum inhibition of each parasite line is measured in IgG before depletion. NF54-IgG contained the largest fraction of the inhibitory activity, with mean nBIA values >50% against all isolates and hovering around 100% for most (**Figure 4A**). This included three recently adapted heterologous maternal isolates, which showed both the lowest (M2022170) and highest (M2001190) nBIA levels respectively at 56% and 111% inhibition. Interestingly, titration of the inhibitory capacity of NF54-IgG against the homologous parasite indicated that blocking is achieved at IgG concentration as low as 10µg/mL (**Figure 4-figure supplement 2**). 7G8-IgG showed lower levels of nBIA than NF54-IgG against all heterologous isolates, except against the maternal isolate M2022170 where 7G8-IgG showed similar levels of nBIA to NF54-IgG; as expected 7G8-IgG (and subsequent variant-purified IgG) showed essentially no activity against NF54 parasites (**Figure 4B-E**). Subsequent purifications of IgG on ectodomain variants continued to yield some level of homologous activity, as seen with WF12/7G8, FCR3 and M. Camp (**Figure 4C, E**). Taken together, the IgG purified on VAR2CSA variants clearly demonstrated homologous inhibition activity while displaying high levels of cross-inhibition activity with initial purifications that generally waned with successive purifications. Despite significant heterologous IE surface reactivities captured on the NF54 antigen, subsequent IgG purifications on other variants captured some level blocking activity against both homologous and heterologous parasites (generally at a lower level than that of NF54-IgG).

Figure 4: CSA-binding inhibitory activity of VAR2CSA-specific purified IgG from multigravidae

To confirm our finding that IgG purified on the first VAR2CSA variant displays the highest level of activities against various VAR2CSA-expressing isolates, we permuted the order of antigens in a second sequential purification/depletion experiment, where IgG to M. Camp, FCR3 and NF54 variants of full-length VAR2CSA were sequentially purified (**Figure 5, figure supplement 1**). IgG purified on the initial variant (M. Camp) exhibited the highest cross-reactivity to heterologous variants of recombinant VAR2CSA (**Figure 5A**) and native antigen expressed by CSA-binding isolates (**Figure 5B**). In the functional assay, M. Camp-IgG strongly cross-inhibited the binding of M. Camp, FCR3 and NF54 parasites to CSA (**Figure 5C, 5D and 5E**). This observation is consistent with the pattern observed with IgG purified on NF54 variant of VAR2CSA in the first purification/depletion experiment.

Figure 5: Activity of VAR2CSA-specific sequentially purified IgG from multigravidae in second independent experiments

Discussion

VAR2CSA is the leading vaccine candidate to protect malaria-exposed pregnant women against PM and related adverse outcomes. Two vaccines based on VAR2CSA fragments have been recently tested in clinical trials (Mordmuller et al., 2019, Sirima et al., 2020), showing good safety and immunogenicity but a general inability to induce broadly neutralizing antibodies, such as those described in sera of PM-resistant multigravid women (Fried and Duffy, 1998; Ricke et al., 2000; Duffy and Fried, 2003; Ndam et al., 2015). The limitations of VAR2CSA domain-based subunit vaccines have also been established from the studies of naturally acquired antibodies in PM-resistant multigravidae, where single domains or domain combinations from different variants failed to deplete heterologous binding-inhibition activity (Doritchamou et al., 2016). Among the probable explanations, the restricted array of protective epitopes displayed by VAR2CSA subunit vaccines, as well as the contribution of antibodies targeting other variants or antigens (including non-VAR2CSA proteins), are of major interest. It is therefore likely that larger fragments of VAR2CSA would offer a broader spectrum of functional epitopes including conformational epitopes and those present in other fragments missing from the subunits tested. Supporting this hypothesis, the present data demonstrate that strain-transcending naturally acquired anti-adhesion antibodies can be purified on a single recombinant VAR2CSA ectodomain, providing additional evidence that define VAR2CSA as the major target of functional antibodies.

This conclusion is well-supported by previous studies showing that naturally acquired anti-adhesion antibodies in PM target VAR2CSA (Bigey et al., 2011; Doritchamou et al., 2016), even though other invariant proteins are highly expressed by placental parasites (Francis et al., 2007; Fried et al., 2007; Tuikue Ndam et al., 2008; Bertin et al., 2013). Anti-adhesion activity of antibodies targeting these invariant proteins has not been reported thus far, and whether these proteins play a role in parasite binding to CSA is still unclear. Our data demonstrate that the removal of IgG specific to five variants of VAR2CSA ectodomain significantly reduced/abolished IE-surface reactivity and the CSA-binding inhibition activity of total IgG from multigravidae. This observation suggests that antibodies to surface-expressed non-VAR2CSA proteins might have limited or no blocking activity against CSA-binding parasites, although a synergistic effect of these antibodies with anti-VAR2CSA cannot be excluded.

Naturally acquired antibodies of malaria-exposed multigravid women recognize placenta-binding parasites from diverse geographical origins (Fried and Duffy, 1998; Ricke et al., 2000). One leading hypothesis is that pregnant women acquire antibodies to both cross-reactive and variant-specific epitopes over successive pregnancies and exposure to diverse placenta-binding parasites. We show here that the purification of IgG to VAR2CSA recombinants resulted in loss of IE surface reactivity against the three homologous parasites, and significantly reduced heterologous cross-reactivity of total IgG to maternal isolates. Consequently, the VAR2CSA-purified IgG exhibited strong cross reactivity to all isolates tested in this study, with IgG purified on the first variant demonstrating the highest level of cross-reactivity to diverse CSA-binding isolates. Of note, the isolates under study included WF12/7G8 that expresses the South American VAR2CSA 7G8 allele, in addition to isolates from South East Asia (M Camp), East Africa (M0736) and West Africa (NF54, M2022170, M2001190), thus representing geographically diverse origins. Overall, it may be difficult to estimate

the fraction of variant-specific or cross-reactive antibodies contributed by each variant to the measured activities, knowing that each sequence of VAR2CSA could have multiple epitopes that are variably shared with some or all variants (Benavente et al., 2018; Otto et al., 2019). However, highly cross-reactive antibodies can be purified from a single recombinant VAR2CSA ectodomain, suggesting that immunization with a single variant may prove highly effective.

The full-length VAR2CSA ectodomain-based vaccine approach has been previously investigated in preclinical studies in which antisera raised in rodent models had strong homologous functional activity (Khunrae et al., 2010). However, these antibodies generated in rodents did not cross-inhibit different CSA-binding isolates, while exhibiting a broadly strain-transcending surface reactivity to these isolates (Avril et al., 2011). In contrast to this observation, our data demonstrate that naturally acquired IgG specific to a single variant and purified from multigravidae sera cross-inhibited multiple isolates. Notably, most of the binding-inhibition activity to CSA-binding parasites was depleted on the first variant and the resulting IgG purified on NF54 (in the first experiment) or M. Camp (in the second experiment) demonstrated strain-transcending blocking activity to all isolates tested in this study. Antibody response to VAR2CSA may differ between species or may differ based on exposure to vaccine antigen or to natural infection. For example, recently published data demonstrated that naturally acquired PfEMP1-specific antibodies are strongly afucosylated, while immunization with a subunit (VAR2CSA) vaccine results in fully fucosylated specific IgG (Larsen et al., 2021). Future studies that investigate differences in the host immune response to VAR2CSA in human versus other species will also elucidate any discrepancies between the functional activity of human versus rodent antibody.

Our data support the idea that one VAR2CSA variant might induce antibody with broad functional activity, acknowledging the challenges in developing a full-length VAR2CSA-based vaccine (reviewed in (Doritchamou et al., 2021)), including the possibility that non-functional epitopes may interfere with the optimal functional antibody response. It is also possible that the flanking flexible arm composed of DBL5 ϵ -6 ϵ or DBL5 ϵ -7 ϵ (in some cases) may play a role in masking functional epitopes on the core (NTS-ID3) structure of VAR2CSA (Doritchamou et al., 2019; Ma et al., 2021). Although recombinant expression of full-length VAR2CSA may not be feasible for manufacturing, novel technologies such as mRNA vaccine platform (reviewed in (Pardi et al., 2018)) should be explored in future studies. To conclude, we report that naturally acquired antibody purified on VAR2CSA ectodomains exhibited strong strain-transcending surface reactivity and blocking activity to CSA-binding isolates. Interestingly, IgG purified against a single variant captured the bulk of strain-transcending IE reactivity and CSA-binding inhibition activity from total IgG of PM-resistant multigravidae. Therefore, the full-length VAR2CSA ectodomain appears to display both variant-specific and shared epitopes targeted by functional antibodies and as such, would be a credible alternative to the VAR2CSA subunit approach in PM vaccine development. Moreover, cross-reactive antibodies could result from both conserved linear epitopes and conformational (tertiary structure related) epitopes, and the human monoclonal antibody PAM1.4 (Barfod et al., 2007) provides strong evidence of the latter. Although such antibodies may contribute to the broadly neutralizing activity of VAR2CSA-specific IgG described in this study, quantifying their relative contribution will inform future PM vaccine development.

Key Resources Table				
Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
Antibody	Goat anti-Human IgG Fc - Affinity Pure, HRP Conjugate (goat polyclonal)	ImmunoReagents , Inc	GtxHu-004-DHRPX	1:3000 dilution
Antibody	Goat anti-Human IgG Fc Secondary Antibody, PE, eBioscience™ (goat polyclonal)	Invitrogen, Carlsbad, CA	12-4998-82	1:800 dilution
Biological samples (Human)	Plasma	Malaria Research and Training Centre, Bamako, Mali	Fried et al., 2018	
Protein, recombinant protein	Full-length VAR2CSA ectodomain, variant NF54	Patrick E Duffy	Renn et al., 2021	
Protein, recombinant protein	Full-length VAR2CSA ectodomain, variant 7G8	Patrick E Duffy	Renn et al., 2021	
Protein, recombinant protein	Full-length VAR2CSA ectodomain, variant FCR3	Patrick E Duffy	Renn et al., 2021	

Protein, recombinant protein	Full-length VAR2CSA ectodomain, variant HB3	Patrick E Duffy	Renn et al., 2021	
Protein, recombinant protein	Full-length VAR2CSA ectodomain, variant M920	Patrick E Duffy	Renn et al., 2021	
Protein, recombinant protein	Full-length VAR2CSA ectodomain, variant M. Camp	Patrick E Duffy	Renn et al., 2021	
Protein, recombinant protein	Full-length VAR2CSA ectodomain, variant M200101	Patrick E Duffy	Renn et al., 2021	
Strain, strain background (<i>Plasmodium falciparum</i>)	NF54	Patrick E Duffy	Doritchamou et al., 2019	
Strain, strain background (<i>Plasmodium falciparum</i>)	FCR3	Patrick E Duffy	Doritchamou et al., 2016	
Strain, strain background (<i>Plasmodium falciparum</i>)	M. Camp	Patrick E Duffy		
Strain, strain background (<i>Plasmodium falciparum</i>)	M0736	Patrick E Duffy	Doritchamou et al., 2016	
Strain, strain background (<i>Plasmodium falciparum</i>)	M2022170	Patrick E Duffy		

Strain, strain background (<i>Plasmodium falciparum</i>)	M2001190	Patrick E Duffy		
Strain, strain background (<i>Plasmodium falciparum</i>)	WF12	Thomas E Wellems, NIH	Hayton et al., 2008	
commercial assay or kit	NHS-Activated Sepharose 4 Fast Flow	GE Healthcare Life Sciences	17090601	
chemical compound, drug	SYBR™ Green I Nucleic Acid Gel Stain - 10,000X	LifeTechnologies	S7563	Used at 0.1X
software, algorithm	Graphpad PRISM 9.0	GraphPad Software, Inc.		
software, algorithm	FlowJo 10	Tree Star, Inc.		
software, algorithm	R package 'ape'	http://ape-package.ird.fr/		

287

288 **Plasma pool, recombinant full-length VAR2CSA and *P. falciparum* cultures**

289 For this study, a plasma pool was prepared using samples from multigravid women participating in
290 the previously described Immuno-epidemiology (IMEP) study (Fried et al., 2018). Briefly, pregnant
291 women aged 15–45 years without clinical evidence of chronic or debilitating illness were enrolled
292 from 2010-2013 into a longitudinal cohort study of mother-infant pairs conducted in
293 Ouélessébougou, Mali. All participants provided signed informed consent after receiving a study
294 explanation form and oral explanation from a study clinician in their native language. The study
295 protocol and study procedures were approved by the institutional review board of the National
296 Institute of Allergy and Infectious Diseases at the US National Institutes of Health (ClinicalTrials.gov
297 ID NCT01168271), and the Ethics Committee of the Faculty of Medicine, Pharmacy and Dentistry at
298 the University of Bamako, Mali. Aliquots of the plasma pools used in the IgG purification/depletion

experiments are fractions of two larger stocks prepared by pooling up to 500ul of plasma from two batches of 119 and 98 randomly selected multigravid women.

Recombinant full-length VAR2CSA ectodomains of seven genetically diverse *P. falciparum* parasite strains (NF54, 7G8, FCR3, HB3, M. Camp, M920 and M200101) (**Figure 2-figure supplement 4**) were expressed in a mammalian expression system as in a previous study (Renn et al., 2021). Three CSA-binding maternal isolates (M2022170, M2001190 and M0736) expressing VAR2CSA as well as four lab-strains ((NF54, FCR3, M. Camp and WF12/7G8, a progeny of 7G8 X GB4 (Hayton et al., 2008) that encodes the 7G8 VAR2CSA variant) selected to bind CSA (**Supplementary File 1**) were maintained in culture for the functional assays.

Purification of IgG specific to full-length VAR2CSA ectodomains

Total IgG was initially purified from 4 mL of the multigravidae plasma pool using Protein G Sepharose 4 Fast Flow resin (GE Healthcare Life Sciences) according to the manufacturer's instructions. For VAR2CSA-specific IgG purification and depletion, an antigen-specific affinity column was prepared as previously described (Doritchamou et al., 2016) for each VAR2CSA variant. Briefly, each ectodomain variant was chemically cross-linked to N-hydroxysuccinimide (NHS)-activated Sepharose beads (GE Healthcare Life Sciences) according to the manufacturer's instructions. IgG specific to five VAR2CSA variants (NF54, 7G8, FCR3, HB3 and MC) were sequentially removed from the total IgG by passage through the affinity column and by applying the flow-through sample from one column to the next column until all specificities were depleted (**Figure 1: Flow chart**). IgG purification was performed repeatedly on each VAR2CSA antigen to ensure complete depletion of the specific IgG. The purified IgG were eluted with IgG Elution buffer, pH 2.8 (Invitrogen, Carlsbad, CA), neutralized with 2M Tris buffer pH 9.0, and dialyzed into PBS pH 7.4. Variable number of passages were needed for full depletion of NF54 (x 3), 7G8 (x 3), FCR3 (x 2), HB3 (x 1) and M. Camp (x 1) specific IgG. The different aliquots of purified IgG were quantified using a Nanodrop (ND2000, Thermo Fisher Scientific, Waltham, MA).

Reactivity of the naturally acquired IgG to VAR2CSA recombinants and VAR2CSA-expressing isolates

Total IgG (before and after each variant-specific depletion) or VAR2CSA-specific IgG purified on each the five ectodomain variants was assessed by ELISA as previously described (Doritchamou et al., 2019). Briefly, recombinant VAR2CSA proteins were coated at 1 µg/mL and incubated overnight at 4°C. Plates were blocked at room temperature (RT) for 2 hours (h) and 100 µL of total IgG at 10 µg/mL and VAR2CSA-specific IgG at 0.1 µg/mL were added in duplicate wells for 1h at RT. The plates were washed and 100 µL of 1:3000 diluted HRP-conjugated anti-human IgG antibody (ImmunoReagents, Inc) added to each well for 1h incubation at RT followed by a final wash. One hundred microliters TMB (SeraCare) was added to each well for 10 min of incubation in dark at RT and the reaction was stopped by adding an equal volume of Stop Solution (SeraCare). Optical density (OD) values at 450 nm were acquired using the MultiskanFC (Thermo Fisher) plate reader.

IgG reactivity to native VAR2CSA expressed on IE surface was assessed by flow cytometry using 6 isolates of *P. falciparum* as previously described (Doritchamou et al., 2016). Briefly, enriched mature trophozoite/schizont stages of IE were incubated with total IgG (at 100 µg/mL) or the antigen-

specific IgG (at 1 µg/mL), washed, and bound IgG labeled with PE-conjugated anti-human IgG (Invitrogen, Carlsbad, CA) in a buffer containing 0.1% SYBR (LifeTechnologies). IgG-labeled IE were quantified using an LSRII flow cytometer (BD Biosciences, San Jose, CA) and analyzed in FlowJo 10 (Tree Star, Inc.). The median fluorescence intensity (MFI) was determined and background intensity from a well containing IE without immune IgG was subtracted from the MFI value detected for each test IgG.

Inhibition of IE binding to CSA

The CSA-binding inhibition activity of the purified IgG was evaluated in a static binding inhibition assay using immobilized CSPG receptor as previously described (Doritchamou et al., 2016). Briefly, the proteoglycan decorin (Sigma) at 2 µg/mL in 1X PBS was coated as 15 µL spots on a 100×15 mm Petri dish (Falcon 351029) by overnight incubation at 4°C in a humid chamber. The spots were blocked with 3% BSA in 1X PBS at 37°C for 30 min. Before binding assay, enriched mature trophozoite/schizont stages of IE from different *P. falciparum* strains were adjusted to 20% parasite density at 0.5% hematocrit and incubated with total IgG (at 1, 2 and 4 mg/mL) or VAR2CSA-specific IgG (at 0.1 mg/mL) for 30 min at 37°C. IE suspended in IgG solution were then allowed to bind duplicate receptor spots for 30 min at RT. Unbound IE were washed away and bound IE were fixed, stained and quantified by microscopy. The percentage of inhibition was calculated relative to the wells containing IE without IgG.

Acknowledgements

This work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. The authors thank J. Patrick Gorres for editing the manuscript and Robert Morrison for bioinformatic analysis. We are grateful to women in Ouélessébougou, Mali for participation in the IMEP study.

Competing Interests

The authors declare that no conflicts of interest are associated with this manuscript.

References

- Ataíde, R., V. Mwapasa, M.E. Molyneux, S.R. Meshnick, and S.J. Rogerson. 2011. Antibodies That Induce Phagocytosis of Malaria Infected Erythrocytes: Effect of HIV Infection and Correlation with Clinical Outcomes. *PLOS ONE*. 6:e22491. doi:10.1371/journal.pone.0022491.
- Avril, M., M.J. Hathaway, A. Srivastava, S. Dechavanne, M. Hommel, J.G. Beeson, J.D. Smith, and B. Gamain. 2011. Antibodies to a Full-Length VAR2CSA Immunogen Are Broadly Strain-Transcendent but Do Not Cross-Inhibit Different Placental-Type Parasite Isolates. *PLoS ONE*. 6:e16622. doi:10.1371/journal.pone.0016622.

375 Barfod, L., N.L. Bernasconi, M. Dahlbäck, D. Jarrossay, P.H. Andersen, A. Salanti, M.F. Ofori,
376 L. Turner, M. Resende, M.A. Nielsen, T.G. Theander, F. Sallusto, A. Lanzavecchia, and
377 L. Hviid. 2007. Human pregnancy-associated malaria-specific B cells target polymorphic,
378 conformational epitopes in VAR2CSA. *Molecular Microbiology*. 63:335–347.
379 doi:https://doi.org/10.1111/j.1365-2958.2006.05503.x.

380 Benavente, E.D., D.R. Oresgun, P.F. de Sessions, E.M. Walker, C. Roper, J.G. Dombrowski,
381 R.M. de Souza, C.R.F. Marinho, C.J. Sutherland, M.L. Hibberd, F. Mohareb, D.A. Baker,
382 T.G. Clark, and S. Campino. 2018. Global genetic diversity of var2csa in Plasmodium
383 falciparum with implications for malaria in pregnancy and vaccine development. *Scientific*
384 *Reports*. 8:15429. doi:10.1038/s41598-018-33767-3.

385 Bertin, G.I., A. Sabbagh, F. Guillonnet, S. Jafari-Guemouri, S. Ezinmegnon, C. Federici, B.
386 Hounkpatin, N. Fievet, and P. Deloron. 2013. Differential Protein Expression Profiles
387 Between Plasmodium falciparum Parasites Isolated From Subjects Presenting With
388 Pregnancy-Associated Malaria and Uncomplicated Malaria in Benin. *J. Infect. Dis.*
389 208:1987–1997. doi:10.1093/infdis/jit377.

390 Bigey, P., S. Gnidehou, J. Doritchamou, M. Quiviger, F. Viwami, A. Couturier, A. Salanti, M.A.
391 Nielsen, D. Scherman, P. Deloron, and N. Tuikue Ndam. 2011. The NTS-DBL2X region
392 of VAR2CSA induces cross-reactive antibodies that inhibit adhesion of several
393 Plasmodium falciparum isolates to chondroitin sulfate A. *J. Infect. Dis.* 204:1125–1133.
394 doi:10.1093/infdis/jir499.

395 Brabin, B.J. 1983. An analysis of malaria in pregnancy in Africa. *Bulletin of the World Health*
396 *Organization*. 61:1005.

397 Chêne, A., S. Gangnard, C. Dechavanne, S. Dechavanne, A. Srivastava, M. Tétard, S. Hundt, O.
398 Leroy, N. Havelange, N.K. Viebig, and B. Gamain. 2018. Down-selection of the
399 VAR2CSA DBL1-2 expressed in E. coli as a lead antigen for placental malaria vaccine
400 development. *NPJ Vaccines*. 3:28. doi:10.1038/s41541-018-0064-6.

401 Clausen, T.M., S. Christoffersen, M. Dahlback, A.E. Langkilde, K.E. Jensen, M. Resende, M.O.
402 Agerbaek, D. Andersen, B. Berisha, S.B. Ditlev, V.V. Pinto, M.A. Nielsen, T.G.
403 Theander, S. Larsen, and A. Salanti. 2012. Structural and Functional Insight into How the
404 Plasmodium falciparum VAR2CSA Protein Mediates Binding to Chondroitin Sulfate A in
405 Placental Malaria. *Journal of Biological Chemistry*. 287:23332–23345.
406 doi:10.1074/jbc.M112.348839.

407 Dahlbäck, M., L.M. Jørgensen, M.A. Nielsen, T.M. Clausen, S.B. Ditlev, M. Resende, V.V.
408 Pinto, D.E. Arnot, T.G. Theander, and A. Salanti. 2011. The chondroitin sulfate A-binding
409 site of the VAR2CSA protein involves multiple N-terminal domains. *J. Biol. Chem.*
410 286:15908–15917. doi:10.1074/jbc.M110.191510.

411 Desai, M., F.O. ter Kuile, F. Nosten, R. McGready, K. Asamo, B. Brabin, and R.D. Newman.
412 2007. Epidemiology and burden of malaria in pregnancy. *Lancet Infect Dis*. 7:93–104.
413 doi:10.1016/S1473-3099(07)70021-X.

414 Doritchamou, J.Y.A., R. Herrera, J.A. Aebig, R. Morrison, V. Nguyen, K. Reiter, R.L. Shimp,
 415 N.J. MacDonald, D.L. Narum, M. Fried, and P.E. Duffy. 2016. VAR2CSA Domain-
 416 Specific Analysis of Naturally Acquired Functional Antibodies to Plasmodium falciparum
 417 Placental Malaria. *J. Infect. Dis.* 214:577–586. doi:10.1093/infdis/jiw197.

418 Doritchamou, J.Y.A., R. Morrison, J.P. Renn, J. Ribeiro, J. Duan, M. Fried, and P.E. Duffy. 2019.
 419 Placental malaria vaccine candidate antigen VAR2CSA displays atypical domain
 420 architecture in some Plasmodium falciparum strains. *Commun Biol.* 2:457.
 421 doi:10.1038/s42003-019-0704-z.

422 Doritchamou, J.Y.A., J. Suurbaar, and N.T. Ndam. 2021. Progress and new horizons toward a
 423 VAR2CSA-based placental malaria vaccine. *Expert Review of Vaccines.* 20:215–226.
 424 doi:10.1080/14760584.2021.1878029.

425 Duffy, P.E., and M. Fried. 2003. Antibodies that inhibit Plasmodium falciparum adhesion to
 426 chondroitin sulfate A are associated with increased birth weight and the gestational age of
 427 newborns. *Infect. Immun.* 71:6620–6623.

428 Francis, S.E., V.A. Malkov, A.V. Oleinikov, E. Rossnagle, J.P. Wendler, T.K. Mutabingwa, M.
 429 Fried, and P.E. Duffy. 2007. Six genes are preferentially transcribed by the circulating and
 430 sequestered forms of Plasmodium falciparum parasites that infect pregnant women. *Infect.*
 431 *Immun.* 75:4838–4850. doi:10.1128/IAI.00635-07.

432 Fried, M., M. Avril, R. Chaturvedi, P. Fernandez, J. Lograsso, D. Narum, M.A. Nielsen, A.V.
 433 Oleinikov, M. Resende, A. Salanti, T. Saveria, K. Williamson, A. Dicko, A. Scherf, J.D.
 434 Smith, T.G. Theander, and P.E. Duffy. 2013. Multilaboratory approach to preclinical
 435 evaluation of vaccine immunogens for placental malaria. *Infect. Immun.* 81:487–495.
 436 doi:10.1128/IAI.01106-12.

437 Fried, M., and P.E. Duffy. 1996. Adherence of Plasmodium falciparum to chondroitin sulfate A in
 438 the human placenta. *Science.* 272:1502–1504.

439 Fried, M., and P.E. Duffy. 1998. Maternal malaria and parasite adhesion. *J. Mol. Med.* 76:162–
 440 171.

441 Fried, M., K.K. Hixson, L. Anderson, Y. Ogata, T.K. Mutabingwa, and P.E. Duffy. 2007. The
 442 distinct proteome of placental malaria parasites. *Mol. Biochem. Parasitol.* 155:57–65.
 443 doi:10.1016/j.molbiopara.2007.05.010.

444 Fried, M., J.D. Kurtis, B. Swihart, R. Morrison, S. Pond-Tor, A. Barry, Y. Sidibe, S. Keita, A.
 445 Mahamar, N. Andemel, O. Attaher, A.B. Dembele, K.B. Cisse, B.S. Diarra, M.B.
 446 Kanoute, D.L. Narum, A. Dicko, and P.E. Duffy. 2018. Antibody levels to recombinant
 447 VAR2CSA domains vary with Plasmodium falciparum parasitaemia, gestational age, and
 448 gravidity, but do not predict pregnancy outcomes. *Malaria Journal.* 17:106.
 449 doi:10.1186/s12936-018-2258-9.

450 Gardner, M.J., N. Hall, E. Fung, O. White, M. Berriman, R.W. Hyman, J.M. Carlton, A. Pain,
451 K.E. Nelson, and S. Bowman. 2002. Genome sequence of the human malaria parasite
452 *Plasmodium falciparum*. *Nature*. 419:498–511.

453 Guyatt, H.L., and R.W. Snow. 2001. Malaria in pregnancy as an indirect cause of infant mortality
454 in sub-Saharan Africa. *Trans. R. Soc. Trop. Med. Hyg.* 95:569–576.

455 Hayton, K., D. Gaur, A. Liu, J. Takahashi, B. Henschen, S. Singh, L. Lambert, T. Furuya, R.
456 Bouttenot, M. Doll, F. Nawaz, J. Mu, L. Jiang, L.H. Miller, and T.E. Wellems. 2008.
457 Erythrocyte Binding Protein PfRH5 Polymorphisms Determine Species-Specific Pathways
458 of *Plasmodium falciparum* Invasion. *Cell Host Microbe*. 4:40–51.
459 doi:10.1016/j.chom.2008.06.001.

460 Hviid, L., and A.T.R. Jensen. 2015. Chapter Two - PfEMP1 – A Parasite Protein Family of Key
461 Importance in *Plasmodium falciparum* Malaria Immunity and Pathogenesis. *In* *Advances*
462 *in Parasitology*. D. Rollinson and J.R. Stothard, editors. Academic Press. 51–84.

463 Keen, J., L. Serghides, K. Ayi, S.N. Patel, J. Ayisi, A. van Eijk, R. Steketee, V. Udhayakumar,
464 and K.C. Kain. 2007. HIV impairs opsonic phagocytic clearance of pregnancy-associated
465 malaria parasites. *PLoS Med.* 4:e181. doi:10.1371/journal.pmed.0040181.

466 Khunrae, P., M. Dahlbäck, M.A. Nielsen, G. Andersen, S.B. Ditlev, M. Resende, V.V. Pinto, T.G.
467 Theander, M.K. Higgins, and A. Salanti. 2010. Full-length recombinant *Plasmodium*
468 *falciparum* VAR2CSA binds specifically to CSPG and induces potent parasite adhesion-
469 blocking antibodies. *J. Mol. Biol.* 397:826–834. doi:10.1016/j.jmb.2010.01.040.

470 Kraemer, S.M., and J.D. Smith. 2006. A family affair: var genes, PfEMP1 binding, and malaria
471 disease. *Current Opinion in Microbiology*. 9:374–380. doi:10.1016/j.mib.2006.06.006.

472 Larsen, M.D., M. Lopez-Perez, E.K. Dickson, P. Ampomah, N. Tuikue Ndam, J. Nouta, C.A.M.
473 Koeleman, A.L.H. Ederveen, B. Mordmüller, A. Salanti, M.A. Nielsen, A. Massougbodji,
474 C.E. van der Schoot, M.F. Ofori, M. Wuhler, L. Hviid, and G. Vidarsson. 2021.
475 Afucosylated *Plasmodium falciparum*-specific IgG is induced by infection but not by
476 subunit vaccination. *Nat Commun.* 12:5838. doi:10.1038/s41467-021-26118-w.

477 Ma, R., T. Lian, R. Huang, J.P. Renn, J.D. Petersen, J. Zimmerberg, P.E. Duffy, and N.H. Tolia.
478 2021. Structural basis for placental malaria mediated by *Plasmodium falciparum*
479 VAR2CSA. *Nature Microbiology*. 6:380–391. doi:10.1038/s41564-020-00858-9.

480 Moore, K.A., J.A. Simpson, M.J.L. Scoullar, R. McGready, and F.J.I. Fowkes. 2017.
481 Quantification of the association between malaria in pregnancy and stillbirth: a systematic
482 review and meta-analysis. *Lancet Glob Health*. 5:e1101–e1112. doi:10.1016/S2214-
483 109X(17)30340-6.

484 Mordmüller, B., M. Sulyok, D. Egger-Adam, M. Resende, W.A. de Jongh, M.H. Jensen, H.H.
485 Smedegaard, S.B. Ditlev, M. Soegaard, L. Poulsen, C. Dyring, C.L. Calle, A. Knoblich, J.
486 Ibáñez, M. Esen, P. Deloron, N. Ndam, S. Issifou, S. Houard, R.F. Howard, S.G. Reed, O.
487 Leroy, A.J.F. Luty, T.G. Theander, P.G. Kremsner, A. Salanti, and M.A. Nielsen. 2019.

- First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria. *Clin. Infect. Dis.* 69:1509–1516. doi:10.1093/cid/ciy1140.
- Ndam, N.T., L. Denoeud-Ndam, J. Doritchamou, F. Viwami, A. Salanti, M.A. Nielsen, N. Fievet, A. Massougboji, A.J.F. Luty, and P. Deloron. 2015. Protective Antibodies against Placental Malaria and Poor Outcomes during Pregnancy, Benin. *Emerging Infect. Dis.* 21:813–823. doi:10.3201/eid2105.141626.
- Nielsen, M.A., and A. Salanti. 2015. High-Throughput Testing of Antibody-Dependent Binding Inhibition of Placental Malaria Parasites. In *Malaria Vaccines: Methods and Protocols*. A. Vaughan, editor. Springer, New York, NY. 241–253.
- Otto, T.D., S.A. Assefa, U. Böhme, M.J. Sanders, D. Kwiatkowski, M. Berriman, and C. Newbold. 2019. Evolutionary analysis of the most polymorphic gene family in *falciparum* malaria. *Wellcome Open Res.* 4. doi:10.12688/wellcomeopenres.15590.1.
- Pardi, N., M.J. Hogan, F.W. Porter, and D. Weissman. 2018. mRNA vaccines — a new era in vaccinology. *Nat Rev Drug Discov.* 17:261–279. doi:10.1038/nrd.2017.243.
- Renn, J.P., J.Y.A. Doritchamou, B.C.N. Tentokam, R.D. Morrison, M.V. Cowles, M. Burkhardt, R. Ma, N.H. Tolia, M. Fried, and P.E. Duffy. 2021. Allelic variants of full-length VAR2CSA, the placental malaria vaccine candidate, differ in antigenicity and receptor binding affinity. *Commun Biol.* 4:1–12. doi:10.1038/s42003-021-02787-7.
- Ricke, C.H., T. Staaloe, K. Koram, B.D. Akanmori, E.M. Riley, T.G. Theander, and L. Hviid. 2000. Plasma antibodies from malaria-exposed pregnant women recognize variant surface antigens on *Plasmodium falciparum*-infected erythrocytes in a parity-dependent manner and block parasite adhesion to chondroitin sulfate A. *J. Immunol.* 165:3309–3316.
- Salanti, A., M. Dahlbäck, L. Turner, M.A. Nielsen, L. Barfod, P. Magistrado, A.T.R. Jensen, T. Lavstsen, M.F. Ofori, K. Marsh, L. Hviid, and T.G. Theander. 2004. Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. *J. Exp. Med.* 200:1197–1203. doi:10.1084/jem.20041579.
- Salanti, A., T. Staaloe, T. Lavstsen, A.T.R. Jensen, M.P.K. Sowa, D.E. Arnot, L. Hviid, and T.G. Theander. 2003. Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering *Plasmodium falciparum* involved in pregnancy-associated malaria. *Molecular Microbiology.* 49:179–191. doi:10.1046/j.1365-2958.2003.03570.x.
- Sirima, S.B., L. Richert, A. Chêne, A.T. Konate, C. Champion, S. Dechavanne, J.-P. Semblat, N. Benhamouda, M. Bahuaud, P. Loulergue, A. Ouédraogo, I. Nébié, M. Kabore, D. Kargougou, A. Barry, S.M. Ouattara, V. Boilet, F. Allais, G. Roguet, N. Havelange, E. Lopez-Perez, A. Kuppers, E. Konaté, C. Roussillon, M. Kanté, L. Belarbi, A. Diarra, N. Henry, I. Soulama, A. Ouédraogo, H. Esperou, O. Leroy, F. Batteux, E. Tartour, N.K. Viebig, R. Thiebaut, O. Launay, and B. Gamain. 2020. PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised,

527 double-blind, placebo-controlled study. *Lancet Infect Dis.* 20:585–597.
528 doi:10.1016/S1473-3099(19)30739-X.

529 Steketee, R.W., B.L. Nahlen, M.E. Parise, and C. Menendez. 2001. The burden of malaria in
530 pregnancy in malaria-endemic areas. *Am. J. Trop. Med. Hyg.* 64:28–35.

531 Tuikue Ndam, N., E. Bischoff, C. Proux, T. Lavstsen, A. Salanti, J. Guitard, M.A. Nielsen, J.-Y.
532 Coppée, A. Gaye, T. Theander, P.H. David, and P. Deloron. 2008. Plasmodium falciparum
533 Transcriptome Analysis Reveals Pregnancy Malaria Associated Gene Expression. *PLoS*
534 *ONE.* 3:e1855. doi:10.1371/journal.pone.0001855.

535 Tuikue Ndam, N.G., A. Salanti, G. Bertin, M. Dahlbäck, N. Fievet, L. Turner, A. Gaye, T.
536 Theander, and P. Deloron. 2005. High level of var2csa transcription by Plasmodium
537 falciparum isolated from the placenta. *J. Infect. Dis.* 192:331–335. doi:10.1086/430933.

538 Wang, K., R. Dagil, T. Lavstsen, S.K. Misra, C.B. Spliid, Y. Wang, T. Gustavsson, D.R.
539 Sandoval, E.E. Vidal-Calvo, S. Choudhary, M.Ø. Agerbaek, K. Lindorff-Larsen, M.A.
540 Nielsen, T.G. Theander, J.S. Sharp, T.M. Clausen, P. Gourdon, and A. Salanti. 2021.
541 Cryo-EM reveals the architecture of placental malaria VAR2CSA and provides molecular
542 insight into chondroitin sulfate binding. *Nat Commun.* 12:2956. doi:10.1038/s41467-021-
543 23254-1.

544

545

Figure legends

Figure 1: Flow chart of the experimental design. VAR2CSA-specific IgG was sequentially purified from total IgG isolated in multigravidae (MG) using antigen-specific columns made with NF54, 7G8, FCR3, HB3, Malayan Camp (M. Camp) alleles of full-length VAR2CSA ectodomain. The flow-through IgG as well as eluted IgG after each VAR2CSA column were assessed by ELISA, in Flow cytometry for surface reactivity and binding inhibition assay using CSA-binding *Plasmodium falciparum*-infected red blood cells (RBC). Image was created with BioRender.com

Figure 2: Depletion of VAR2CSA-specific IgG and activity of Total IgG purified from Malian multigravidae. Activity of the total IgG before (Pre-depletion) and after (Post-depletion) purification of VAR2CSA-specific IgG was assessed by **(A)** ELISA on different recombinant full-length VAR2CSA ectodomain, **(B)** by Flow cytometry, and **(C)** CSA-binding inhibition assay using six isolates including three recently adapted maternal isolates (M0736, M2022170 and M2001190). In panel B, histogram without IgG represents assay well with no testing IgG and similarly stained with conjugated anti-human secondary IgG. In panel C, percent inhibition activity of purified IgG was determined relative to activity obtained with control wells without any testing IgG. Data in C represent at least two independent experiments. Asterisk (*) indicates antigens used in the sequential VAR2CSA-specific IgG depletion assay.

Figure 3: Reactivity of the purified VAR2CSA-specific IgG to different full-length VAR2CSA antigens and *P. falciparum* isolates. Reactivity of VAR2CSA-specific purified IgG was assessed by ELISA **(A)** on seven recombinant full-length VAR2CSA ectodomain proteins including two proteins (M920 and M200101) that were not used in the purification assay. IgG were tested at 0.1 µg/mL concentration (IgG conc.); asterisk (*) indicates depleted reactivity. **(B)** Ability of purified VAR2CSA IgG to bind native VAR2CSA on six CSA-binding isolates was evaluated by Flow cytometry. Testing IgG is indicated in red while histogram in blue represents assay well with no testing IgG and similarly stained with conjugated anti-human secondary IgG. Median fluorescence intensity (MFI) values are indicated. Due to limited material of purified IgG on HB3 VAR2CSA (HB3-IgG), no data (ND) are available for maternal isolates (M0736, M2022170 and M2001190). Asterisk (*) indicates surface reactivity to the homologous parasite.

Figure 4: CSA-binding inhibitory activity of VAR2CSA-specific purified IgG from multigravidae. The inhibition capacity of VAR2CSA-specific purified IgG was assessed on CSA-binding isolates **(A – E)**. Blocking activity (nBIA) of purified IgG was normalized by activity obtained with total IgG before any VAR2CSA IgG purification (Pre-depletion). Due to limited material, purified IgG on FCR3, HB3 and M. Camp was not tested on maternal isolates (M0736, M2022170 and M2001190). Black box indicates inhibition activity against homologous parasite and empty box represents activity against heterologous parasites. Data represent at least two independent experiments.

Figure 5: Reactivity of the purified VAR2CSA-specific IgG to different full-length VAR2CSA antigens and *P. falciparum* isolates in a second independent purification/depletion experiment. Reactivity of VAR2CSA-specific purified IgG was assessed by ELISA **(A)** on seven recombinant full-length VAR2CSA ectodomain proteins including four proteins (7G8, HB3, M920 and M200101) that were not used in this purification/depletion assay. IgG were tested at 0.1 µg/mL

concentration. **(B)** Ability of purified VAR2CSA IgG to bind native VAR2CSA on six CSA-binding isolates was evaluated by Flow cytometry. Testing IgG is indicated in red while histogram in blue represents assay well with no testing IgG and similarly stained with conjugated anti-human secondary IgG. Median fluorescence intensity (MFI) values are indicated. Asterisk (*) indicates surface reactivity to homologous parasite. **(C– E)** Inhibition capacity of the VAR2CSA-specific purified IgG was assessed on three CSA-binding isolates. Black box indicates inhibition activity to the homologous parasite and empty box represent activities against heterologous parasites.

Figure 2-figure supplement 1: Reactivity of the post depletion samples to VAR2CSA recombinants and CSA-binding isolates. Reactivity of initial total IgG (MG total IgG) as well as flow through (FT) IgG samples collected after each VAR2CSA-specific column were assessed by ELISA **(A)** on seven recombinant full-length VAR2CSA ectodomain proteins. IgG were tested at 10 µg/mL concentration (IgG conc.). **(B)** Ability of MG total IgG and FT IgG to bind native VAR2CSA on CSA-binding isolates was evaluated by Flow cytometry. Testing IgG is indicated in red while histogram in blue represents assay well with no testing IgG and similarly stained with conjugated anti-human secondary IgG. Median fluorescence intensity (MFI) values are indicated. For maternal isolate M2022170, no data (ND) are available for FT samples collected after NF54, 7G8, FCR3 and HB3 due to limited material.

Figure 2-figure supplement 2: VAR2CSA sequences shared by progeny of 7G8 and GB4 crossing. VAR2CSA sequences of seven progenies of 7G8 x GB4 crossing were analyzed using the Consensus Protein Pileup (CPP) tool in R package ‘DuffyNGS’ as previously described (Doritchamou et al., 2019; Renn et al., 2021). Sequence similarity among the seven variants was measured as edit distance which was determined as the number of mismatched residues of amino acid, using R function ‘adist()’. Progenies including WF12 (grey row) sharing the same VAR2CSA sequence as 7G8 are highlighted in the red box, while those with GB4 sequence are in the purple box.

Figure 2-figure supplement 3: Percent reduction in CSA-binding inhibition activity of the MG-Pool after VAR2CSA IgG purification/depletion. Percent reduction in inhibition activity after depletion of reactivities to five variants of full-length VAR2CSA ectodomain is shown.

Figure 2-figure supplement 4: Phylogenetic analysis of variants of full-length VAR2CSA sequences

Phylogenetic trees were generated using function ‘plot.phylo()’ from the R package ‘ape’. The NTS-DBL6 truncated sequence of the M200101 variant (NTS-DBL7) was also included in the analysis.

Figure 4-figure supplement 1: CSA-binding inhibitory activity of VAR2CSA-specific IgG purified from multigravidae. The inhibition capacity of VAR2CSA-specific purified IgG was assessed on CSA-binding isolates **(A – E)**. Percent inhibition activity of purified IgG was determined relative to activity obtained with control wells without any testing IgG. Due to limited material, purified IgG on FCR3, HB3 and M. Camp was not tested on maternal isolates (M0736, M2022170 and M2001190). Black box indicates inhibition activity to the homologous parasite and empty box represents activities against heterologous parasites. Data represent at least two independent experiments.

Figure 4-figure supplement 2: Titration of homologous inhibition activity by purified VAR2CSA_{NF54} specific IgG. Homologous inhibition activity of naturally acquired IgG specific to VAR2CSA_{NF54} ectodomain was assessed by testing variable concentrations (100, 25, 10, 5 and 2.5 µg/mL). Data represent at least two independent experiments.

Figure 5-figure supplement 1: Reactivity of the post depletion samples to VAR2CSA recombinants and CSA-binding isolates. Reactivity of pre-depletion total IgG (T-IgG) as well as flow through (FT) IgG samples collected after each VAR2CSA-specific column was assessed by ELISA **(A)** on seven recombinant full-length VAR2CSA ectodomain proteins. IgG were tested at 10 µg/mL concentration. IE-surface reactivity of IgG evaluated by Flow cytometry is shown in panel **(B)**. Testing IgG is indicated in red while histogram in blue represents assay well with no testing IgG and similarly stained with conjugated anti-human secondary IgG. Median fluorescence intensity (MFI) values are provided.

Supplementary File 1: CSA-binding level of the isolates

Figure 2-figure supplement 1: Reactivity of the post depletion samples to VAR2CSA recombinants and CSA-binding isolates

Figure 2-figure supplement 2: VAR2CSA sequences shared by progeny of 7G8 and GB4 crossing

> Edit.Distance.Matrix

	Parent_7G8	C7G8xGB4_D2	C7G8xGB4_DEV	C7G8xGB4_WE2	C7G8xGB4_WF12	C7G8xGB4_XF12	C7G8xGB4_AL2	C7G8xGB4_AUD	Parent_GB4
Parent_7G8	0	0	0	0	0	54	645	645	645
C7G8xGB4_D2	0	0	0	0	0	54	645	645	645
C7G8xGB4_DEV	0	0	0	0	0	54	645	645	645
C7G8xGB4_WE2	0	0	0	0	0	54	645	645	645
C7G8xGB4_WF12	0	0	0	0	0	54	645	645	645
C7G8xGB4_XF12	54	54	54	54	54	0	638	638	638
C7G8xGB4_AL2	645	645	645	645	645	638	0	0	0
C7G8xGB4_AUD	645	645	645	645	645	638	0	0	0
Parent_GB4	645	645	645	645	645	638	0	0	0

Figure 2-figure supplement 3: Percent reduction in CSA-binding inhibition activity of the MG-Pool after VAR2CSA IgG purification/depletion

Figure 2-figure supplement 4: Phylogenetic analysis of variants of full-length VAR2CSA sequences

Figure 4-figure supplement 1: CSA-binding inhibitory activity of VAR2CSA-specific IgG purified from multigravidae

Figure 4-figure supplement 2: Titration of purified VAR2CSA_{NF54} specific IgG homologous inhibition activity

Figure 5-figure supplement 1 : Reactivity of the post depletion samples to VAR2CSA recombinants and CSA-binding isolates